Back to Search
Start Over
Effectiveness of switching from first-generation basal insulin to Glargine 300 U/mL in children and adolescents with type 1 diabetes: results from the ISPED CARD database.
Effectiveness of switching from first-generation basal insulin to Glargine 300 U/mL in children and adolescents with type 1 diabetes: results from the ISPED CARD database.
- Source :
-
Acta diabetologica [Acta Diabetol] 2024 Sep; Vol. 61 (9), pp. 1169-1176. Date of Electronic Publication: 2024 May 24. - Publication Year :
- 2024
-
Abstract
- Aims: Glargine 300 U/mL (Gla-300) has been recently approved for use in children and adolescents with type 1 diabetes (T1D). However, real-world effectiveness data are scarce, and aim of this analysis was to assess clinical outcomes in young patients with T1D switching from 1st generation basal insulin (1BI) to Gla-300.<br />Methods: ISPED CARD is a retrospective, multicenter study, based on data anonymously extracted from Electronic Medical Records. The study involved a network of 20 pediatric diabetes centers. Data on all patients aged < 18 years with T1D switching from 1BI to Gla-300 were analyzed to assess clinical characteristics at the switch and changes after 6 and 12 months in glycated hemoglobin (HbA1c), fasting blood glucose (FBG), and standardized body mass index (BMI/SDS). Titration of basal and short-acting insulin doses was also evaluated.<br />Results: Overall, 200 patients were identified. The mean age at the switch to Gla-300 was 13 years, and mean duration of diabetes was 3.9 years. Average HbA1c levels at switch were 8.8%. After 6 months, HbA1c levels decreased by - 0.88% (95% CI - 1.28; - 0.48; p < 0.0001). The benefit was maintained after 12 months from the switch (mean reduction of HbA1c levels - 0.80%, 95% CI - 1.25; - 0.35, p = 0.0006). Trends of reduction in FBG levels were also evidenced both at 6 months and 12 months. No significant changes in short-acting and basal insulin doses were documented.<br />Conclusions: The study provides the first real-world evidence of the effectiveness of Gla-300 in children and adolescents with T1D previously treated with 1BI. The benefits in terms of HbA1c levels reduction were substantial, and sustained after 12 months. Additional benefits can be expected by improving the titration of insulin doses.<br /> (© 2024. Springer-Verlag Italia S.r.l., part of Springer Nature.)
- Subjects :
- Humans
Adolescent
Male
Child
Female
Retrospective Studies
Insulin administration & dosage
Insulin therapeutic use
Treatment Outcome
Databases, Factual
Drug Substitution statistics & numerical data
Diabetes Mellitus, Type 1 drug therapy
Diabetes Mellitus, Type 1 blood
Insulin Glargine administration & dosage
Insulin Glargine therapeutic use
Hypoglycemic Agents administration & dosage
Hypoglycemic Agents therapeutic use
Glycated Hemoglobin analysis
Glycated Hemoglobin metabolism
Blood Glucose drug effects
Blood Glucose metabolism
Blood Glucose analysis
Subjects
Details
- Language :
- English
- ISSN :
- 1432-5233
- Volume :
- 61
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Acta diabetologica
- Publication Type :
- Academic Journal
- Accession number :
- 38789610
- Full Text :
- https://doi.org/10.1007/s00592-024-02304-2